Table 3 |
|
|
Major pharmacological treatment for neuropathic pain and their basic mechanisms |
|
|
Compound |
Mode of action |
|
|
|
|
Antidepressants |
|
|
Nortriptyline |
Inhibition of both serotonin and norepinephrine reuptake |
|
Desipramine |
Inhibition of both serotonin and norepinephrine reuptake |
|
Duloxetine |
Inhibition of both serotonin and norepinephrine reuptake |
|
Venlafaxine |
Inhibition of both serotonin and norepinephrine reuptake |
|
Anticonvulsants |
|
|
Gabapentin |
Decreases release of glutamate, norepinephrine, and substance P, with ligands on α2-δ subunit of voltage |
|
Pregabalin |
Decreases release of glutamate, norepinephrine, and substance P, with ligands on α2-δ subunit of voltage |
|
Lacosamide |
Decreases release of presynaptic transmitters, inhibition of voltage-gated sodium-channel. |
|
Opioid agonists |
|
|
Morphine |
μ-receptor agonism |
|
Oxycodone |
μ-receptor agonism |
|
Methadone |
μ-receptor agonism,κ-receptor antagonism |
|
Levorphanol |
μ-receptor agonism |
|
Tramadol |
μ-receptor agonism, inhibition of norepinephrine and serotonin reuptake |
|
Topical therapy |
|
|
5% lidocaine patch |
Block of sodium channels |
|
High-dose capsaicin patch |
Damage of nociceptive sensory axons, a highly selective activating ligand for TRPV1,. |
|
Botulinum toxin. |
Inhibition of both the exocytosis of acetylcholine and some other neurotransmitters |
|
|
|
|
Xu et al. Molecular Pain 2012 8:15 doi:10.1186/1744-8069-8-15 |
|